RxSight, Inc. (NASDAQ:RXST) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC reduced its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 27.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 425,322 shares of the company's stock after selling 161,201 shares during the period. Gilder Gagnon Howe & Co. LLC owned 1.06% of RxSight worth $14,623,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Two Sigma Securities LLC acquired a new stake in shares of RxSight during the fourth quarter worth $200,000. Nebula Research & Development LLC raised its stake in RxSight by 18.6% in the 4th quarter. Nebula Research & Development LLC now owns 43,201 shares of the company's stock valued at $1,485,000 after acquiring an additional 6,778 shares during the period. RiverPark Advisors LLC raised its position in shares of RxSight by 54.8% in the fourth quarter. RiverPark Advisors LLC now owns 7,432 shares of the company's stock valued at $256,000 after purchasing an additional 2,632 shares during the period. Coppell Advisory Solutions LLC lifted its position in RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock worth $44,000 after acquiring an additional 672 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of RxSight during the fourth quarter worth $441,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the transaction, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

RXST has been the topic of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $43.00 price target on shares of RxSight in a research note on Thursday, April 3rd. Bank of America reiterated an "underperform" rating and issued a $22.00 target price (down from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Stifel Nicolaus cut their target price on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Piper Sandler began coverage on shares of RxSight in a report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective on the stock. Finally, UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, RxSight has a consensus rating of "Hold" and an average price target of $37.60.

RxSight Stock Up 0.6 %

NASDAQ:RXST traded up $0.09 on Thursday, hitting $14.81. The stock had a trading volume of 331,435 shares, compared to its average volume of 640,684. The business's 50-day simple moving average is $21.22 and its two-hundred day simple moving average is $33.24. The stock has a market cap of $601.38 million, a price-to-earnings ratio of -17.86 and a beta of 1.26. RxSight, Inc. has a 52-week low of $13.50 and a 52-week high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. As a group, equities research analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.